By Paul Ziobro
Trevi Therapeutics said a study regarding the human-abuse potential of an oral drug to treat chronic cough in certain patients yielded positive results.
The company on Tuesday said that a study of oral nalbuphine showed clinical doses of the drug demonstrated a statistically significant lower "drug liking" compared with intravenous butorphanol. Meanwhile, a supratherpeutic dose was numerically lower than the intravenous butorphanol, but the results were not statistically significant.
James Cassella, Trevi's chief development officer, said the company was pleased with the results.
Trevi is developing the Haduvio, an oral naluphine extended release drug that treats chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist, which are opioid receptors that play a key role in controlling cough.
Nalbuphine is currently unscheduled in the U.S. and has been for several decades, according to Jack Henningfield, vice president of research, health policy and abuse liability at Pinney Associates. Part of the study is to demonstrate that the drug doesn't pose the same safety risks as do other opioids that are often prescribed for chronic cough.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
December 03, 2024 17:30 ET (22:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。